Table 1.
Baseline characteristics of LACI-1 participants.
| All | Both delayed | ISMN | Cilostazol | Both immediate | |
|---|---|---|---|---|---|
| Patients | 57 | 15 | 15 | 13 | 14 |
| Age (years)* | 66.1 (11.1) | 63.4 (11.5) | 62.2 (11.0) | 75.8 (8.7) | 64.4 (8.1) |
| Sex, female | 18 (31.6%) | 6 (40.0%) | 4 (26.7%) | 5 (38.5%) | 3 (21.4%) |
| Onset to randomization (days) | 202.6 (256.2) | 153.3 (180.4) | 137.5 (214.2) | 279.2 (324.7) | 254.0 (290.7) |
| Systolic BP (mmHg) | 147.3 (20.5) | 141.8 (19.6) | 150.9 (19.0) | 146.1 (21.3) | 150.4 (22.9) |
| Diastolic BP (mmHg) | 83.3 (12.6) | 82.9 (14.3) | 86.6 (11.5) | 79.3 (12.0) | 83.7 (12.6) |
| Past medical history (%) | |||||
| Treated hypertension | 42 (73.7%) | 11 (73.3%) | 11 (73.3%) | 12 (92.3%) | 8 (57.1%) |
| Treated hyperlipidaemia | 48 (84.2%) | 11 (73.3%) | 12 (80.0%) | 13 (100.0%) | 12 (85.7%) |
| Diabetes | 11 (19.3%) | 3 (20.0%) | 3 (20.0%) | 2 (15.4%) | 3 (21.4%) |
| Atrial fibrillation | 0 | 0 | 0 | 0 | 0 |
| Myocardial infarction | 1 (1.8%) | 1 (6.7%) | 0 | 0 | 0 |
| Previous stroke | 6 (10.5%) | 1 (6.7%) | 2 (13.3%) | 1 (7.7%) | 2 (14.3%) |
| Smoking | 26 (45.6%) | 10 (66.7%) | 6 (40.0%) | 6 (46.2%) | 4 (28.6%) |
| Patient status | |||||
| mRS, baseline [/6] | 1.0 [0.0, 1.0] | 1.0 [0.0, 2.0] | 1.0 [1.0, 1.0] | 1.0 [1.0, 1.0] | 1.0 [0.0, 1.0] |
| Current NIHSS [/42] | 0.0 [0.0, 1.0] | 0.0 [0.0, 1.0] | 0.0 [0.0, 1.0] | 0.0 [0.0, 1.0] | 0.5 [0.0, 1.0] |
BP, blood pressure; ISMN, isosorbide mononitrate; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale.
*
Significant difference between the treatment groups (p <0.05), comparisons done and Kruskal-Wallis tests.